{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:16:21Z","timestamp":1758845781244,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,8,19]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The 2015 UK guidelines for HER2 assessment in breast cancer recommended repeat assessment if the core biopsy was scored as 2+ on HER2 immunohistochemistry (IHC) with borderline negative in situ hybridisation (ratio of number of HER2 to chromosome 17 centromere copies of 1.8\u20131.99). This case series aimed to assess the value of such repeat assessment in the surgical specimen, in particular the proportion that were HER2 positive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Details of biopsies with 2+ IHC\u2009and borderline negative in situ hybridisation were extracted from a database. The results of repeat HER2 testing in the surgical specimen for this cohort study were then obtained.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>112 patients with no preoperative treatment had repeat assessment: 4 were 3+ and 16 were 2+ amplified. Of 14 with preoperative chemotherapy, 1 was 3+ and 4 were 2+ amplified. All the 2+ amplified carcinomas had a HER2 to chromosome 17 ratio less than 4, in 50% the ratio was between 2.0 and 2.2, and in 50% the HER2 copy number was less than 4.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Repeat assessment yielded 4% 3+ results\u2009and 14% 2+ amplified carcinomas but with low level amplification. These results suggest that retesting of borderline negative HER2 cases should be optional and no longer mandatory.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp-2023-209091","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:20:29Z","timestamp":1693401629000},"page":"726-729","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Should a borderline negative HER2 result in a core biopsy of invasive carcinoma of the breast have HER2 assessment repeated in the excision specimen?"],"prefix":"10.1136","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-4050","authenticated-orcid":false,"given":"Andrew H S","family":"Lee","sequence":"first","affiliation":[{"name":"Histopathology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Hodi","sequence":"additional","affiliation":[{"name":"Histopathology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"},{"name":"Source BioScience plc, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeg","family":"Abbas","sequence":"additional","affiliation":[{"name":"Histopathology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wencyk","sequence":"additional","affiliation":[{"name":"Source BioScience plc, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian O","family":"Ellis","sequence":"additional","affiliation":[{"name":"Histopathology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"},{"name":"Source BioScience plc, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-5525","authenticated-orcid":false,"given":"Emad","family":"Rakha","sequence":"additional","affiliation":[{"name":"Histopathology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"2025092504171886000_77.11.726.1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202571"},{"key":"2025092504171886000_77.11.726.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp234"},{"key":"2025092504171886000_77.11.726.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.04144.x"},{"key":"2025092504171886000_77.11.726.4","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2022-208632"},{"key":"2025092504171886000_77.11.726.5","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.054866"},{"key":"2025092504171886000_77.11.726.6","unstructured":"Ellis IO , Al-Sam S , Anderson N , et al . Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. Royal College of Pathologists, 2016."},{"key":"2025092504171886000_77.11.726.7","doi-asserted-by":"publisher","DOI":"10.1309\/J9VXABUGKC4Y07DL"},{"key":"2025092504171886000_77.11.726.8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3801021"},{"key":"2025092504171886000_77.11.726.9","doi-asserted-by":"publisher","DOI":"10.1159\/000521880"},{"key":"2025092504171886000_77.11.726.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"2025092504171886000_77.11.726.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"2025092504171886000_77.11.726.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"2025092504171886000_77.11.726.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05295-9"},{"key":"2025092504171886000_77.11.726.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01351-8"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2023-209091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:17:29Z","timestamp":1758799049000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2023-209091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,10,20]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jcp-2023-209091"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2023-209091","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}